Prokidney Corp PROK 价格预测与展望

Q: 技术分析指标如何适用于 PROK？

根据技术分析，Prokidney Corp 的综合信号为 Sell。Prokidney Corp 有 1 个买入信号，2 个中性信号和 4 个卖出信号。

Q: PROK 的斐波那契回调水平是多少？

Prokidney Corp 的斐波那契回调水平是 在 23.6% 和 38.2% 之间。

Q: Prokidney Corp 的 RSI 是多少？

Prokidney Corp 的 RSI 目前为 49.68，表明处于 中立 状态

Q: Prokidney Corp 接下来 12 个月的价格是多少？

Prokidney Corp PROK 接下来 12 个月的价格预计为 $6.84。

Q: Prokidney Corp 预计会涨到多高？

据华尔街分析师称，Prokidney Corp 预计将达到 $12.6 的高预测值。

主页

股票

PROK

预测

PROK 股票价格预测

Prokidney Corp

$2.23

2.57%

$0.05

截至今日：Jan 20, 10:26:20 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$2.18

开盘价

$2.21

当日区间

$2.16 - $2.31

52周范围

$0.46 - $7.13

交易量

1.5M

平均成交量

1.3M

每股收益（TTM）

-0.54

股息收益率

市值

$672.7M

什么是 PROK？

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

功能特性

交易策略

资源

市场

Utilizing our sophisticated predictive model, we anticipate notable price fluctuations for PROK in the upcoming periods. Looking toward the future, our 2027 projection indicates an average price target of $6.84. The lowest target is $1.01 and the highest is $12.6. Empower your investment choices with our cutting-edge, data-driven analysis!

PROK 股价预测摘要

PROK的顶级分析师评级

基于 14 位分析师对 PROK 的股票评级，更新于 Sep 01, 2025

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for PROK. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: PROK is a Buy candidate.

PROK stock price ended at $2.29 on 星期五, after rising 5.05%

On the latest trading day Jan 16, 2026, the stock price of PROK rose by 5.05%, climbing from $2.21 to $2.29. During the session, the stock saw a volatility of 6.91%, with prices oscillating between a daily low of $2.17 and a high of $2.32. Notably, trading volume dropped by 271.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.5M shares were traded, equating to a market value of approximately $688.9M.

PROK 技术面信号

技术面信号摘要

购买信号 1

中性信号 2

卖出信号 4

Strong Sell

Sell

Neutral

Buy

Strong Buy

PROK目前显示1个买入信号和4个卖出信号。该股票自12:00 AM以来一直处于上升趋势状态，在此期间价格总变动为5.05%。总体而言，技术指标显示中期前景为Sell。

PROK 的看涨/看跌信号

我们的算法通过分析移动平均线、RSI、MACD 和成交量等关键指标，为 PROK 生成看涨和看跌信号。这些见解可助您做出明智的投资决策。

后续问题

技术分析指标如何适用于 PROK？



PROK 的斐波那契回调水平是多少？



Prokidney Corp 的 RSI 是多少？



Prokidney Corp 接下来 12 个月的价格是多少？



Prokidney Corp 预计会涨到多高？



Prokidney Corp（PROK）价格

PROK 股价走势图